LAE113 / Laekna Therap - LARVOL DELTA

Laikai Pharmaceuticals-B (02105) appeared at the 2023 SITC annual meeting with 2 achievements, and the international recognition of its innovation capabilities and configuration value were simultaneously improved. [Google translation] (Investing.com) - "On November 1, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego, California, USA, Laika Medical-B (02105) announced the preclinical results of two independently developed new bispecific antibodies in the form of a poster. Data: LILRB1-B2 bispecific antibody (LAE111) that modulates T/NK/myeloid cell function, and TIGIT-PVRIG bispecific antibody (LAE113) that modulates T/NK cell function....When LAE113 is combined with PD-L1 monoclonal antibody (LAE005), it shows a synergistic effect in enhancing the secretion of IFN-γ by CD8+ T cells. In addition, when combined with antibodies that mediate ADCC effects, it significantly enhances the activity of NK cells and the effects of ADCC. LAE113 significantly inhibited tumor growth in the HuPBMC A375 xenograft model, outperforming clinical-stage control antibodies."

Preclinical • Oncology

LAE113, a novel TIGIT/PVRIG bispecific antibody for the treatment of cancer (SITC 2023) - "Conclusions LAE113 is an extremely potent TIGIT and PVRIG signaling blocker, outperforming existing competitors (Tiragolumab, COM701, SHR-2002 and SIM0348) in modulating T cell and NK cell functions, and exhibiting a favorable developability profile. It significantly enhanced T cell activity when combined with PD-L1 blockade. These findings suggest that LAE113 holds great promise as a candidate for cancer immunotherapy."

Oncology • CD8 • IFNG • NECTIN2 • PVR • TIGIT

Laekna, Inc. (2105.HK) Announces Interim Results 2023 (PRNewswire) - "We have advanced three PCC drug candidates from our internal discovery platform: LAE111, a LILRB1 and LILRB2 bispecific antibody; LAE113, a TIGIT-PVRIG bispecific antibody; and LAE112, a FGFR2b monoclonal antibody....EXPECTED UPCOMING MILESTONES: (i) Presenting LAE111/LILRB1-2 bispecific antibody as a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 38th annual meeting in San Diego, California, U.S., in November 2023; (ii) Presenting LAE113/TIGIT/PVRIG bispecific antibody as a poster presentation at the SITC 38th annual meeting in San Diego, California, U.S., in November 2023."

New molecule • Preclinical • Oncology